Cannara Biotech Past Earnings Performance
Past criteria checks 5/6
Cannara Biotech has been growing earnings at an average annual rate of 81.1%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 64.3% per year. Cannara Biotech's return on equity is 11.1%, and it has net margins of 13.6%.
Key information
81.1%
Earnings growth rate
81.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 64.3% |
| Return on equity | 11.1% |
| Net Margin | 13.6% |
| Last Earnings Update | 30 Nov 2023 |
Recent past performance updates
Recent updates
Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28
Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Revenue & Expenses BreakdownBeta
How Cannara Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Nov 23 | 66 | 9 | 15 | 1 |
| 31 Aug 23 | 57 | 7 | 14 | 1 |
| 31 May 23 | 51 | 5 | 13 | 1 |
| 28 Feb 23 | 45 | 3 | 11 | 1 |
| 30 Nov 22 | 40 | 3 | 11 | 1 |
| 31 Aug 22 | 36 | 2 | 10 | 1 |
| 31 May 22 | 30 | 1 | 10 | 1 |
| 28 Feb 22 | 27 | 1 | 9 | 1 |
| 30 Nov 21 | 22 | 1 | 8 | 2 |
| 31 Aug 21 | 17 | -2 | 7 | 2 |
| 31 May 21 | 11 | -7 | 7 | 2 |
| 28 Feb 21 | 5 | -11 | 7 | 3 |
| 30 Nov 20 | 3 | -13 | 8 | 3 |
| 31 Aug 20 | 3 | -12 | 9 | 3 |
| 31 May 20 | 3 | -12 | 11 | 2 |
| 29 Feb 20 | 2 | -12 | 12 | 1 |
| 30 Nov 19 | 2 | -13 | 11 | 0 |
| 31 Aug 19 | 2 | -12 | 11 | 0 |
| 31 Aug 18 | 1 | -4 | 4 | 0 |
Quality Earnings: LOVE has high quality earnings.
Growing Profit Margin: LOVE's current net profit margins (13.6%) are higher than last year (7.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LOVE has become profitable over the past 5 years, growing earnings by 81.1% per year.
Accelerating Growth: LOVE's earnings growth over the past year (218.8%) exceeds its 5-year average (81.1% per year).
Earnings vs Industry: LOVE earnings growth over the past year (218.8%) exceeded the Pharmaceuticals industry 22%.
Return on Equity
High ROE: LOVE's Return on Equity (11.1%) is considered low.